iCAD's Breast Health Solutions are built on deep learning technology and deliver powerful software solutions for breast tomosynthesis, breast density, risk assessment and 2D mammography. These innovative solutions offer clinicians a wide range of tools for disease detection and analysis that enhance workflow and improve overall efficiency. Our Breast Health Solutions support healthcare facilities worldwide in providing quality breast care to their patients.
New and improved: PowerLook® Density Assessment is the world’s first and only deep-learning multi-vendor automated breast density assessment algorithm for synthesized 2D images.
This solution uses an appearance-based approach to assess dense tissue, to deliver automated, rapid and reproducible assessments of breast structure, texture, and fibroglandular dispersion, with greater accuracy than ever before. This innovative technique calibrates the patient’s breast density to the appropriate density category corresponding to BI-RADS reporting system.
*For GE and Hologic only. Uses 2D synthesized images
SecondLook® is based on sophisticated patented algorithms that analyze the data, automatically identifying and marking suspicious regions in 2D mammography images. The solution provides the radiologist with a “second look” which helps the radiologist detect actionable missed cancers earlier than screening mammography alone. SecondLook detects and identifies suspicious masses and micro-calcifications utilizing image processing, pattern recognition and artificial intelligence techniques. Information from thousands of mammography images are incorporated into these algorithms enabling the product to distinguish between characteristics of cancerous and normal tissue.
© iCAD Inc. All rights reserved. iCAD, the iCAD logo, PowerLook, ProFound AI, ProFound, Xoft, the Xoft logo, Axxent, Electronic Brachytherapy System and eBx are registered trademarks of iCAD, Inc. Reproduction of any of the material contained herein in any format or media without the express written permission of iCAD, Inc. is prohibited.